Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the DAISe System During Neurointervention for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 85 years.~* Diagnosis of acute ischemic stroke with study enrollment time \< 8 hours from onset of symptoms.~* Disabling stroke defined as a baseline NIHSS \> 6.~* Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-1.~* If thrombolytic therapy (tPA) is administered, it must be administered per the prescribing information.~* Confirmed symptomatic intracranial occlusion, based on single phase, multiphase or dynamic CTA, at one or more of the following locations: Carotid T/L, M1 MCA, or M1-MCA equivalent (2 or more M2-MCAs), or M2-MCA.~* The following baseline imaging criteria should be met: MRI criterion: ASPECTS Score \> 4 OR CT criterion: ASPECTS \> 6~* Signed informed consent from patient or legally authorized representative.~Exclusion Criteria:~* CT or MRI evidence of recent/ fresh hemorrhage on presentation.~* Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.~* Rapidly improving neurological deficits based on the investigator's clinical judgement.~* Pregnancy~* Severe contrast allergy or absolute contraindication to iodinated contrast.~* No femoral pulses or very difficult endovascular access that will result in an inability to deliver endovascular therapy.~* Evidence of dissection in the carotid or middle cerebral arteries.~* Severe unilateral or bilateral carotid artery stenosis requiring treatment at the time of the procedure as determined during diagnostic angiography.~* Renal failure (serum creatinine level ≥ 4 mg/dL or on dialysis).~* Severe, sustained hypertension (SBP \>185 mmHg or DBP \>110 mmHg).~* Cerebral vasculitis.~* Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.~* Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).~* Seizure due to stroke.~* Platelet count \< 50,000/mm3.~* A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.~* Patient is unable or unwilling complete follow up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DAISe System (Type: EXPERIMENTAL): The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).